Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
SymbioCellTech, LLC currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, PURDY, KYLE A, within 1 distinct art unit. The presence of only a single art unit indicates a narrow technical scope for the pending pharmaceutical application.
As PURDY, KYLE A is the busiest examiner with 1 pending action, the company's current biotechnology prosecution is focused on this individual. This means the outcome of the company's biotechnology filing depends solely on the review and preferences of this one individual. With only a distinct examiner and a distinct art unit involved, the prosecution team can dedicate its resources to addressing the specific requirements of this single examination channel. This focused interaction allows for a deep dive into the examiner's past decisions and the art unit's particular standards to resolve the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18997284 | Species-Specific Tissue Culture Medium for the Propagation of Cells | PURDY, KYLE A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18997284 | Species-Specific Tissue Culture Medium for the Propagation of Cells | PURDY, KYLE A | 1611 | §103 | Non-Final OA | — | Pending | Jan 21, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSymbioCellTech, LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kyle A Purdy has the most, with 1 of SymbioCellTech, LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
